A concerning outbreak of mpox (formerly known as monkeypox) is currently unfolding in the Democratic Republic of Congo, with over 1,000 new cases reported in just one week. The outbreak, linked to a particularly dangerous variant of the virus known as clade 1B, has been exacerbated by public health challenges and resources strained by historical issues in outbreak response and vaccination efforts.
The World Health Organization has characterized mpox as a public health issue, calling for urgent vaccinations, especially given the increasing case numbers not just in Congo but also in other regions, including Africa and beyond. Countries are ramping up efforts for vaccination, with initiatives supported by health organizations and pharmaceutical contracts being put into place for vaccine supplies. For instance, Bavarian Nordic has announced that it will provide millions of doses of both mpox and smallpox vaccines, responding to global demand.
In a bid to tackle the outbreak, Kenya, similarly affected, is set to start its vaccination program against mpox and is assessing its preparedness amid concerns that it may fall short in an emergency. Meanwhile, the mpox virus has also been detected in travelers from Africa to places such as Thailand, prompting health authorities to bolster surveillance and response efforts.
As health systems struggle to manage the crisis, experts express that challenges remain—affecting timely response and vaccination efforts—which is critical for controlling the spread of the virus. The international community's attention toward the disease is increasing, indicating a need for coordinated efforts to confront the threat posed by mpox, particularly in regions where it has been endemic.